secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001104659-22-082999
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE CSO presents InhiBET platform at B&T Cell-Mediated Autoimmune Conference
-----------------------------------------------------------------------------

- CSO Iain Stuart, Ph.D., presented at B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022.
- Presentation covered the InhiBET platform for bromodomain & end terminal (BET) inhibitors in autoimmune disease.
- No new clinical data, financial results, or guidance changes disclosed in the filing or presentation exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922082999/0001104659-22-082999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922082999/tm2221840d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-082999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer